"El Ministerio de Desarrollo e Inclusión Social, creado en el año 2011, es el ente rector de la política social en Perú y el encargado de promover la participación conjunta del sector privado en el desarrollo de alivio de la pobreza. El sector privado ha participado, en las últimas décadas, financiando y ejecutando proyectos de alivio y superación de la pobreza mediante la sociedad civil, Organismos No Gubernamentales (ONG), Entidades e Instituciones Extranjeras de Cooperación Técnica Internacional (ENIEX) y las empresas privadas. El objetivo de este estudio es proveer información sobre las intervenciones que el sector privado viene realizando en los últimos años, así como explorar sus experiencias y lecciones en proyectos de alivio y superación de la pobreza."–Resumen.

Objective: to compare the sale price of essential drugs used in the management and therapy of COVID-19 in public and private pharmacies in Peru. Also, to assess the cost per person of drug therapy for both mild and severe cases. Materials and methods: this is a cross-sectional study using data reported by public and private pharmacies in Peru. Drug prices are presented as median values and they were compared using the non-parametric Kruskal-Wallis test. Also, costs per person and drug accessibility for treating mild and moderate cases were estimated. Results: drugs used when treating mild cases of COVID-19, such as azythromycin, hydroxichloroquine, ivermectin, and paracetamol had median prices between S/ 0.04 (US$ 0.011) and S/ 23.81 (US$ 6.71) in public pharmacies, while the same compounds cost between S/ 1.00 (US$ 0.28) and S/ 36.00 (US$ 10.15) in private pharmacies. On average, drug p...

Objective: to compare the sale price of essential drugs used in the management and therapy of COVID-19 in public and private pharmacies in Peru. Also, to assess the cost per person of drug therapy for both mild and severe cases. Materials and methods: this is a cross-sectional study using data reported by public and private pharmacies in Peru. Drug prices are presented as median values and they were compared using the non-parametric Kruskal-Wallis test. Also, costs per person and drug accessibility for treating mild and moderate cases were estimated. Results: drugs used when treating mild cases of COVID-19, such as azythromycin, hydroxichloroquine, ivermectin, and paracetamol had median prices between S/ 0.04 (US$ 0.011) and S/ 23.81 (US$ 6.71) in public pharmacies, while the same compounds cost between S/ 1.00 (US$ 0.28) and S/ 36.00 (US$ 10.15) in private pharmacies. On average, drug p...